A study comparing the effectiveness of oral versus intravenous ketamine for patients with suicidal thoughts.

A Comparative Interventional Study to assess the efficacy of Intravenous Ketamine versus Oral Ketamine for patients with suicidal ideation - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061125

Enrollment

Registered

2024-01-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F313- Bipolar disorder, current episodedepressed, mild or moderate severity Health Condition 2: F314- Bipolar disorder, current episodedepressed, severe, without psychotic features Health Condition 3: F332- Major depressive disorder, recurrent severe without psychotic features Health Condition 4: F331- Major depressive disorder, recurrent, moderate Health Condition 5: F321- Major depressive disorder, singleepisode, moderate Health Condition 6: F322- Major depressive disorder,

Interventions

Intervention1: Oral Ketamine: Oral Ketamine will be given in dose of 2mg/kg body weight to be sipped orally over 40 minutes. Control Intervention1: Intravenous Ketamine: Intravenous Ketamine will be g

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects aged 18 to 65 years with suicidal ideation having HAMD score more than or equal to 14 and Beck suicidal ideation scale of more than or equal to 5 2. Subjects willing to take Ketamine after informed written consent.

Exclusion criteria

Exclusion criteria: 1. Contraindication to the administration of ketamine, especially present diagnosis or antecedents of clinically relevant cardiovascular disorders such as stroke, heart attack, etc. 2. If they had any, those with present or past diagnosis of glaucoma, intracranial hypertension. 3. Current diagnosis of schizophrenia or other psychotic disorder (including psychotic disorder due to general medical condition, substance-induced psychotic disorder, or mania) as defined in the ICD-11 4. Patients with any known hypersensitivity to ketamine. 5. Subjects having any substance dependence, intoxication or withdrawal within 1 month period

Design outcomes

Primary

Measure	Time frame
Examining decline in "Beck scale for suicide ideation" score in patients after intervention. Timepoint: 2 hours, Day 1, Day 3, Day 7 after intervention.	—

Secondary

Measure	Time frame
Examining the decline in the HAM-D score in patients after intervention.Timepoint: 2 hours, Day 1, Day 3, Day 7 after intervention.	—

Countries

India

Contacts

Public ContactDr. Aneri Amin

Baroda Medical College and SSG Hospital

rakesh_gandhi68@yahoo.com9824299183

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026